With innovative far-field signal reduction technology, the OptiSense lead effectively reduces paced far-field waves by 94% and incidence of inappropriate mode switching by 73%. Clarified atrial sensing provides accurate atrial diagnostics and therapies.
Reduction of Far-Field R Waves by 94%1
Reducing far-field R waves allows for more conffidence in therapy and diagnostics.
Reduction of Inappropriate Mode Switching by 73%1
Compared to conventional leads, OptiSense leads detected less far-field signals at implant, after one month and after three months.
By mitigating paced far-field R waves, OptiSense lead technology reduces the percentage of patients with inappropriate mode switching by 73%. This helps to maintain A-V synchrony, which can increase patient comfort.
More Sensitive Atrial Sensing
By reducing far-field R waves, OptiSense lead technology allows increased atrial sensitivity settings and negates the need to use extended blanking periods. In more than 99% of patients, the atrial sensitivity can be set to 0.3 mV without sensing far-field R waves. This enables sensing of even the finest atrial arrhythmia signals, which translates to better, more appropriate patient care for atrial arrhythmias.
Before OptiSense lead technology, small atrial signals can be undersensed (as shown below).
After OptiSense lead technology, the more sensitive atrial setting picks up the small atrial signals (as shown below).
More Options in Targeted Lead Placement
Some locations in the heart have been shown to result in more physiologic pacing than others. However, until now, atrial leads placed lower on the atrial septal wall were subject to sensing far-field R waves.
OptiSense lead technology allows the lead to be placed in targeted locations in the atrium, minimizing concern for far-field signals. Targeted lead placement may result in more physiologic pacing by allowing for shorter intra-atrial conduction delays and by reducing refractory atrial tachycardia.2
High Performance
-
Shorter tip-to-ring spacing – 1.1 mm - exclusive lead technology, designed to reduce ventricular oversensing, while maintaining near-field P-wave sensing. Accurate sensing reduces inappropriate mode switching, maintaining A-V synchrony.
-
Excellent fluoroscopic visibility – designed to provide easy verification of helix extension/retraction. A main part of the housing material on the tip is constructed of titanium, which is transparent on fluoroscopy. Radiopaque markers underneath the housing make it possible to verify helix extension/retraction.
-
Silicone insulation with Fast-Pass® coating – facilitates lead insertion through the introducer and the veins. \Multiple Lengths (40, 46 and 52 cm) – provide the flexibility to choose the best length for each individual patient.
-
Thin lead body diameter – only 6.2 F - provides ease of passage, facilitates small venous puncture and preserves venous space. The lead can be inserted using a 7 F introducer.
-
Lower thresholds with steroid elution – designed to reduce tissue inflammation at the lead/tissue interface. It also promotes low stimulation thresholds.
-
Reduced polarization with titanium nitride fractal coating – designed to promote precise sensing and to provide improved contact with the myocardium.
1699TC
- Atrial straight lead
- Active fixation (extendable/retractable helix)
- Bipolar
- Tip-to-ring spacing – 1.1 mm
- 40, 46, 52 cm length
1 OptiSense lead Clinical PMA Report, November 2006.
2 Bailin SJ, Adler S, Guidici M. Prevention of chronic atrial fibrillation by pacing in the region of Bachmann's Bundle: Results of a multicenter randomized trial. Journal of Cardiovascular Electrophysiology 2001; 12(8): 912-917.